



## Lumos Pharma to Participate in Upcoming Investor Conferences

November 10, 2021

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- [Lumos Pharma, Inc.](#) (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investor conferences:

Event: **Stifel 2021 Virtual Healthcare Conference – November 16<sup>th</sup> - 17<sup>th</sup>**  
Presentation: Presentation November 16<sup>th</sup> from 3:20-3:50 PM EST  
1x1 Meetings: Virtual one-on-one meetings with management November 16<sup>th</sup> throughout the day  
Webcast link: [Here](#)

Event: **Jefferies London Healthcare Conference – November 16<sup>th</sup> - 19<sup>th</sup>**  
Presentation: Pre-recorded fireside chat available beginning November 18<sup>th</sup> at 8:00 AM GMT / 3:00 AM EST  
1x1 Meetings: One-on-one meetings with management to be held November 18<sup>th</sup> & 19<sup>th</sup> throughout each day  
Webcast link: [Here](#)

Event: **Piper Sandler 33<sup>rd</sup> Annual Virtual Healthcare Conference – November 30<sup>th</sup> - December 2<sup>nd</sup>**  
Presentation: Pre-recorded fireside chat available beginning November 22<sup>nd</sup> at 10:00 AM EST  
1x1 Meetings: One-on-one meetings with management to be held December 1<sup>st</sup> throughout the day  
Webcast link: Available on Lumos Pharma's website ( [here](#) ) as of November 22<sup>nd</sup> at 10:00 AM EST

To schedule a meeting with management during the conferences, please contact your salesperson at the respective firm. Webcasts for each presentation will be available on the Company's website under " [Events & Presentations](#)" in the Investors & Media section.

### About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowthH210 Trial, and a PK/PD trial, the OraGrowthH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit <https://lumos-pharma.com/>.

Investor & Media Contact:

Lisa Miller  
Lumos Pharma Investor Relations  
512-792-5454  
[ir@lumos-pharma.com](mailto:ir@lumos-pharma.com)

Source: Lumos Pharma, Inc.



Source: Lumos Pharma, Inc.